Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
HCV, Breast Cancer Screening Integration Aids Diagnosis, Linkage to Care
Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations
Irbesartan, Sparsentan Treatment Demonstrate Significantly Slower Kidney Function Decline Compared with SoC
Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
Mobile Health Apps Versus Dermatologists: Comparing Preferences for Skin Cancer Screening
Over 20% of PsA Patients Report Widespread Pain, 10% Meet Fibromyalgia Criteria